{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T19:30:06Z","timestamp":1789587006483,"version":"build-2803163510"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,10,23]],"date-time":"2020-10-23T00:00:00Z","timestamp":1603411200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["EClinicalMedicine"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.eclinm.2020.100625","type":"journal-article","created":{"date-parts":[[2020,11,5]],"date-time":"2020-11-05T18:27:52Z","timestamp":1604600872000},"page":"100625","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"special_numbering":"C","title":["Cost-effectiveness of cancer drugs: Comparative analysis of the United States and England"],"prefix":"10.1016","volume":"29-30","author":[{"given":"Avi","family":"Cherla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Renwick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish","family":"Jha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias","family":"Mossialos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eclinm.2020.100625_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/j.socscimed.2020.113042","article-title":"Relationship between costs and clinical benefits of new cancer medicines in Australia, France, the UK, and the US","volume":"258","author":"Salas-Vega","year":"2020","journal-title":"Soc Sci Med"},{"issue":"May 1(5)","key":"10.1016\/j.eclinm.2020.100625_bib0002","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/S1470-2045(20)30139-X","article-title":"Prices and clinical benefit of cancer drugs in the USA and Europe: a cost\u2013benefit analysis","volume":"21","author":"Vokinger","year":"2020","journal-title":"Lancet Oncol [Internet]"},{"issue":"Mar 1(3)","key":"10.1016\/j.eclinm.2020.100625_bib0003","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1001\/jamaoncol.2016.4166","article-title":"Assessment of overall survival, quality of life, and safety benefits associated with new cancer medicines","volume":"3","author":"Salas-Vega","year":"2017","journal-title":"JAMA Oncol [Internet]"},{"issue":"May(5)","key":"10.1016\/j.eclinm.2020.100625_bib0004","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1377\/hlthaff.2015.1453","article-title":"Cancer drugs provide positive value in nine countries, but the united states lags in health gains per dollar spent","volume":"35","author":"Salas-Vega","year":"2016","journal-title":"Health Aff [Internet]"},{"key":"10.1016\/j.eclinm.2020.100625_bib0005","article-title":"Payers\u2019 use of independent reports in decision making \u2013 will there be an ICER effect?","author":"Lising","year":"2017","journal-title":"Value Outcomes Spotlight"},{"key":"10.1016\/j.eclinm.2020.100625_bib0006","first-page":"357","article-title":"Oncology drug health technology assessment recommendations: Canadian versus UK experiences","volume":"6","author":"Chabot","year":"2014"},{"key":"10.1016\/j.eclinm.2020.100625_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.jval.2019.10.010","article-title":"Association between the use of surrogate measures in pivotal trials and health technology assessment decisions: a retrospective analysis of NICE and CADTH reviews of cancer drugs","author":"Pinto","year":"2020","journal-title":"Value Heal"},{"key":"10.1016\/j.eclinm.2020.100625_bib0008","unstructured":"Institute for Clinical and Economic Review. Assessments [Internet]. Available from: https:\/\/icer-review.org\/. Accessed 6 August 2020."},{"key":"10.1016\/j.eclinm.2020.100625_bib0009","doi-asserted-by":"crossref","unstructured":"OECD. Purchasing power parities (PPP) (indicator). doi: 10.1787\/1290ee5a-en. 2019. Accessed 6 August 2020.","DOI":"10.1787\/1290ee5a-en"},{"key":"10.1016\/j.eclinm.2020.100625_bib0010","unstructured":"Institute for Clinical and Economic Review. 2020 Value Assessment Framework: Final Framework [Internet]. [cited 2020 Jun 23]. Available from: https:\/\/icer-review.org\/material\/2020-value-assessment-framework-final-framework\/"},{"key":"10.1016\/j.eclinm.2020.100625_bib0011","unstructured":"The National Institute for Health and Care Excellence. Consultation paper - value based assessment of health technologies [Internet]. 2014 [cited 2020 Aug 6]. Available from: https:\/\/www.nice.org.uk\/Media\/Default\/About\/what-we-do\/NICE-guidance\/NICE-technology-appraisals\/VBA-TA-Methods-Guide-for-Consultation.pdf"},{"issue":"Aug 1(8)","key":"10.1016\/j.eclinm.2020.100625_bib0012","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1001\/jamainternmed.2015.2829","article-title":"The strength of association between surrogate end points and survival in oncology: a systematic review of trial-level meta-analyses","volume":"175","author":"Prasad","year":"2015","journal-title":"JAMA Intern Med [Internet]"},{"key":"10.1016\/j.eclinm.2020.100625_bib0013","unstructured":"NHS England. Cancer Drugs Fund [Internet]. [cited 2020 Aug 5]. Available from: https:\/\/www.england.nhs.uk\/cancer\/cdf\/"},{"key":"10.1016\/j.eclinm.2020.100625_bib0014","unstructured":"OECD. Health spending (indicator). 2020 [cited 2020 Jun 24]; Available from: https:\/\/data.oecd.org\/healthres\/health-spending.htm"},{"issue":"7","key":"10.1016\/j.eclinm.2020.100625_bib0015","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1377\/hlthaff.2017.1553","article-title":"Specialty drug coverage varies across commercial health plans in the US","volume":"37","author":"Chambers","year":"2018","journal-title":"Health Aff"},{"key":"10.1016\/j.eclinm.2020.100625_bib0016","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1001\/jama.2011.152","article-title":"How many \u201cme-too\u201d drugs is too many?","author":"Gagne","year":"2011","journal-title":"JAMA - J Am Med Ass Am Med Ass"},{"key":"10.1016\/j.eclinm.2020.100625_bib0017","unstructured":"The National Institute for Health and Care Excellence [Internet]. NICE; Available from: https:\/\/www.nice.org.uk\/. Accessed 6 August 2020."}],"container-title":["EClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537020303692?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537020303692?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T19:05:22Z","timestamp":1762887922000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537020303692"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":17,"alternative-id":["S2589537020303692"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2020.100625","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-effectiveness of cancer drugs: Comparative analysis of the United States and England","name":"articletitle","label":"Article Title"},{"value":"EClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2020.100625","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100625"}}